BIO Responds To Geron And Roslin Merger

  • Contact: Dan Eramian or Charles Craig
  • Phone: 202-962-9200
  • Recommend
  • Tweet
  • Print
  • Email

WASHINGTON, D.C. (May 4, 1999) Carl B. Feldbaum, president of the Biotechnology Industry Organization, issued the following statement upon the announcement of Geron's acquisition of Roslin Bio-Med and the formation of a research collaboration with the Roslin Institute with the aim of using human pluripotent stem cells, telomerase expression and nuclear transfer to accelerate the development of new transplantation therapies for numerous degenerative diseases such as diabetes, Parkinson's disease, cancer and heart disease:

"Combining these three advanced technologies is both an ambitious and exquisite enterprise. When we look back, we may mark this as one event that launched the new field of regenerative medicine. I expect that we will see more creative scientific and commercial collaborations coming from the biotechnology industry in the year ahead."

BIO represents more than 850 biotechnology companies, academic institutions and state biotechnology centers in 46 states and 26 nations. BIO members are involved in the research and development of health care, agricultural and industrial and environmental biotechnology products.


About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.